Apomorphine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Apomorphine
- Apomorphine: From Parkinson’s Disease to Polymicrogyria, Perisylvian, with Cerebellar Hypoplasia and Arthrogryposis
Apomorphine: From Parkinson’s Disease to Polymicrogyria, Perisylvian, with Cerebellar Hypoplasia and Arthrogryposis
One-Sentence Summary
Apomorphine is a dopamine agonist marketed in the US as injectable products. The evidence pack does not list its approved indication; these products are generally known for Parkinson’s disease, but that was not verified here. The TxGNN model predicts it may be effective for polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis, an ultra-rare congenital malformation. There are 0 clinical trials and 0 publications supporting this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the data provided (see note above) |
| Predicted New Indication | Polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 3 (2 NDAs and 1 ANDA) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Apomorphine is a directly acting dopamine receptor agonist (D1/D2). It is a symptomatic treatment that stimulates dopamine receptors and does not modify disease.
No mechanistic link to this prediction was identified. Perisylvian polymicrogyria with cerebellar hypoplasia and arthrogryposis is a structural congenital malformation of brain development. A symptomatic dopamine agonist has no plausible disease-modifying role in it. The high score (rank 6,785 in the model’s overall ranking) reflects a knowledge-graph association only, not biological or clinical support.
Among the other nine predictions, only two came with retrieved literature or trials:
- Schizophrenia (rank 5, score 99.69%): The evidence is indirect and mostly historical (1975–2003). Apomorphine has been used mainly as a probe of dopamine function. Under the dopamine hypothesis, a dopamine agonist is more likely to aggravate psychosis than treat it, so the direction of effect is questionable.
- Retinal dystrophy (rank 3): The 15 retrieved papers are general reviews and case reports on congenital eye and orbital disorders. None mention apomorphine.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA 214056 | ONAPGO | Injection, solution | Not listed in the data provided |
| NDA 021264 | APOKYN | Injection | Not listed in the data provided |
| ANDA 212025 | Apomorphine hydrochloride (TruPharma) | Injection | Not listed in the data provided |
All three products are injectables.
Safety Considerations
Please refer to the package insert for safety information. No drug interaction records were found in the queried data.
One class-level concern arises from the evidence pack: as a dopamine agonist, apomorphine may worsen psychotic symptoms, which matters for any psychiatric repurposing hypothesis.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (L5), with no trials, no relevant literature, and no plausible mechanism for a symptomatic dopamine agonist in a structural congenital brain malformation.
To proceed, the following is needed:
- Package insert warnings and contraindications from the FDA label, which are currently missing and block safety screening
- Mechanism of action data from DrugBank
- A biological rationale linking dopamine receptor agonism to this malformation
- A drug-level literature search that names apomorphine explicitly
- If a psychiatric direction is pursued, a resolution of the psychosis-aggravation risk before any therapeutic hypothesis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.